Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients
about
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsRegulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservationIssues in solid-organ transplantation in children: translational research from bench to bedside.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Bortezomib use in a pediatric cardiac transplant center.Pediatric heart transplantation-indications and outcomes in the current era.Coincidence of cellular and antibody mediated rejection in heart transplant recipients - preliminary report.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United StatesTolerogenic therapies in transplantation.Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.Increased levels of anti-non-Gal IgG following pig-to-baboon bone marrow transplantation correlate with failure of engraftmentMinimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.New immunosuppressive agents in pediatric transplantation.Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.On the role of HLA antibodies in hematopoietic stem cell transplantation.Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine.Novel therapeutic and diagnostic management of heart transplant patients.The importance of non-HLA antibodies in transplantation.Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.Changes in the methodology of pre-heart transplant human leukocyte antibody assessment: an analysis of the United Network for Organ Sharing database.Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.Results of heart transplantation following failed staged palliation of hypoplastic left heart syndrome and related single ventricle anomalies.Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.Role of C1q complement fixing antibody assay in therapeutic plasma exchange management of pediatric cardiac antibody mediated rejection.Current Expectations for Cardiac Transplantation in Patients With Congenital Heart Disease.
P2860
Q26774993-722CC47C-F215-43AA-8E99-7FA36AD52DFCQ27000202-F19315E5-9C4E-4C7C-AF28-A46874F608F2Q27023312-717CEA8C-B9F4-4342-B04D-AAD81FFF7FFCQ30276550-722B4B6F-7A50-4303-82EC-66F020B6848CQ33415926-975CE5D3-B526-46B7-96DE-1F651AD04922Q34048053-83F585EE-9F91-477D-BCB8-14A42F26322FQ34821994-C51ABC6C-0357-4C94-929E-F50232C875F5Q35957567-6839CA4A-2AEC-4A62-B568-89459BCCEF4FQ36102133-52E20D90-D6B7-4FAD-AB07-6480C5D3BB04Q37231896-4CA68A1D-5922-4DFA-BF7D-74EA28D27666Q37358501-06F44331-9500-48A0-B821-B7DBF6A8ADD0Q37361071-112C2034-1F74-438D-B2CB-A5C5A3A081DBQ37446883-9794197D-8C84-485F-A570-4483F7343A92Q37609092-F5211D94-74DE-4D44-8B11-4EA0ED4F8BC1Q38065269-258FDF38-C825-447A-B708-0AE495309CC4Q38246225-581C439D-3092-49BB-A9C2-705D7002DC0EQ38392458-655B0025-3818-4136-BDC6-BE401E1F2331Q38588170-72F09129-2054-44F8-B19A-6AD9E9DC3B50Q38614686-B953C8C5-D5D4-428E-BDCA-DD8D30699697Q38877375-04433E7F-F22F-487B-A34B-EE089BD7096EQ38945149-76EE6AF6-1A21-45F8-B810-75609D95922EQ40739859-0F1FE84B-4042-46FF-B163-AFA7BD97FE0FQ40990548-3F990B7E-90AA-4B4E-823D-877EA54B6629Q41559290-91925EE5-5F09-4EB2-83BD-62920A7CA80DQ42280145-C4043D3A-61A0-48C5-9B4D-F0BB1B28231CQ42721586-C3B01EF8-1955-408F-9CED-86AEF9D2951FQ46207877-F92533A0-D37D-4627-A6C3-86138D15DC63Q46402292-CFAA51CD-D8F1-43B9-98D3-A85F6D26835BQ48135398-858DBC53-0EDC-4B2E-BAC6-3DC4A3F7E37FQ51102400-4696991D-58A1-499E-BEC3-7D34E903D0DA
P2860
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rapid reduction in donor-speci ...... tric heart transplant patients
@en
Rapid reduction in donor-speci ...... tric heart transplant patients
@nl
type
label
Rapid reduction in donor-speci ...... tric heart transplant patients
@en
Rapid reduction in donor-speci ...... tric heart transplant patients
@nl
prefLabel
Rapid reduction in donor-speci ...... tric heart transplant patients
@en
Rapid reduction in donor-speci ...... tric heart transplant patients
@nl
P2093
P2860
P1433
P1476
Rapid reduction in donor-speci ...... tric heart transplant patients
@en
P2093
E Steve Woodle
Elizabeth A Frazier
Emily L Howard
Kenneth R Knecht
R Neal Smith
Robert D B Jaquiss
Robert L Saylors
Sherry E Pye
Terry O Harville
William Robert Morrow
P2860
P304
P356
10.1097/TP.0B013E31823F7EEA
P577
2012-02-01T00:00:00Z